broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K29905972-001-06-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.26989 | 0.524138 | 0.407258 | 0.786195 | 0.90046 | 3.958132 | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000911 |
BRD-K30577245-001-05-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.21846 | 1.890761 | 0.740565 | 0.477578 | 0.00095 | 0.001288 | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000911 |
BRD-K31698212-001-02-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.448107 | 0.81979 | 0.589143 | 0.82945 | 0.553045 | 8.768076 | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000911 |
BRD-K31928526-001-02-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.27504 | 2.454684 | 0.707047 | 0.685265 | 0.147993 | 0.204903 | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000911 |
BRD-K33379087-001-07-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.388981 | 2.260125 | 0.534836 | 0.756201 | 0.208141 | 0.405073 | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000911 |
BRD-K33610132-001-02-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.052581 | 1.608979 | 0.57646 | 0.867639 | 2.776589 | 2.975123 | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000911 |
BRD-K33622447-066-01-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.800858 | 0.07392 | -0.12778 | 0.871825 | 0.000024 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000911 |
BRD-K35520305-001-16-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.544684 | -0.483475 | -0.008255 | 0.960741 | 0.000149 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000911 |
BRD-K36627727-001-05-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.170524 | -0.387365 | -0.039237 | 1 | 0.028057 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000911 |
BRD-K36788280-001-01-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.86289 | -0.055073 | -0.012735 | 0.926497 | 1.096039 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000911 |
BRD-K37379014-001-02-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.263464 | 7.451844 | 0.708096 | 0.847094 | 0.020806 | 0.023005 | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000911 |
BRD-K38332599-001-01-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.389346 | 1.662294 | 0.341708 | 0.758212 | 0.214599 | 0.531697 | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000911 |
BRD-K38527262-300-01-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.191416 | 3.03068 | 0.600778 | 0.830266 | 1.201274 | 1.408643 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000911 |
BRD-K38852836-001-02-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.525222 | 4.078484 | 0.581011 | 0.677792 | 0.003456 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000911 |
BRD-K39974922-001-04-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.709461 | 9.874135 | 0.376796 | 0.854744 | 0.078138 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000911 |
BRD-K41859756-001-06-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.478638 | 0.314574 | 0.1746 | 0.756979 | 0.03263 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000911 |
BRD-K42495768-001-01-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.926668 | -0.108677 | -0.020812 | 0.943952 | 4,913.257245 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000911 |
BRD-K42805893-001-04-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.189865 | 0.643164 | 0.567317 | 0.687024 | 0.263273 | 0.553224 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000911 |
BRD-K42828737-001-03-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.80929 | 2.113838 | -0.010766 | 0.881254 | 0.023748 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000911 |
BRD-K42898655-001-01-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.308505 | 0.491988 | 0.7352 | 0.447578 | 0.000105 | 0.000741 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000911 |
BRD-K43389675-001-02-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.059576 | 0.899088 | 0.904633 | 0.440406 | 0.030232 | 0.034813 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000911 |
BRD-K44227013-001-06-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.29985 | 4.30754 | 0.781873 | 0.820622 | 0.832164 | 1.02923 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000911 |
BRD-K44408410-001-17-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.13434 | 0.460022 | 0.413672 | 0.716607 | 0.662563 | 1.308073 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000911 |
BRD-K44827188-001-06-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.933129 | -0.108667 | -0.05678 | 0.955318 | 56.508665 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000911 |
BRD-K46386702-001-02-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.276696 | 0.141145 | 0.179829 | 0.595422 | 0.013504 | 4.080347 | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000911 |
BRD-K49328571-001-15-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.140017 | 0.868864 | 0.638071 | 0.680521 | 0.284485 | 0.415224 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000911 |
BRD-K49350383-001-14-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.482434 | 0.190252 | 0.028143 | 1 | 15.397835 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000911 |
BRD-K50010139-001-01-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.323751 | 1.886823 | 0.352422 | 0.33123 | 0.000276 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000911 |
BRD-K50168500-001-07-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.26535 | 0.709808 | 0.913048 | 0.552675 | 0.025129 | 0.072955 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000911 |
BRD-K51313569-001-07-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.421662 | 0.737491 | 0.087501 | 0.789847 | 0.321881 | 3.974046 | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000911 |
BRD-K51791723-003-01-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.097379 | 4.432434 | 0.784998 | 0.763167 | 0.783682 | 0.822932 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000911 |
BRD-K51967704-001-03-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.707127 | 0.588975 | -0.012884 | 0.782263 | 0.004828 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000911 |
BRD-K52313696-001-12-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.492677 | 0.627282 | 0.256829 | 0.855036 | 0.832499 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000911 |
BRD-K53972329-001-07-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.092195 | 0.224984 | 0.024525 | 1 | 0.058143 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000911 |
BRD-K54256913-001-08-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.072622 | 2.524622 | 0.554057 | 0.823676 | 1.585977 | 1.687703 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000911 |
BRD-K54955827-001-02-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.166919 | 0.365214 | 0.276838 | 0.675379 | 0.360288 | 1.095744 | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000911 |
BRD-K54997624-001-06-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.644927 | 1.374623 | 0.338143 | 0.836492 | 0.114717 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000911 |
BRD-K55187425-236-05-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.257302 | 2.790441 | 0.884152 | 0.557725 | 0.030915 | 0.040056 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000911 |
BRD-K56343971-001-14-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.853815 | 0.041154 | -0.031711 | 0.924455 | 0.015199 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000911 |
BRD-K56981171-001-02-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | -1.028434 | 0.985658 | 0.542231 | 0.881865 | 13.468118 | 4.334774 | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000911 |
BRD-K57080016-001-15-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.317426 | 0.228984 | 0.47079 | 0.619666 | 0.025883 | 2.10752 | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000911 |
BRD-K57169635-001-04-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.209925 | 0.915398 | 0.919541 | 0.376022 | 0.00391 | 0.007088 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000911 |
BRD-K58435339-001-03-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.695676 | 0.569402 | 0.348659 | 0.775001 | 0.004906 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000911 |
BRD-K58529924-001-01-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.212858 | 5.205306 | 0.74055 | 0.880324 | 2.42322 | 2.695677 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000911 |
BRD-K58550667-001-08-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.66471 | 2.665008 | 0.317248 | 0.855673 | 0.009584 | null | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000911 |
BRD-K59317601-001-05-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.149744 | 0.898425 | 0.85418 | 0.335352 | 0.004245 | 0.006309 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000911 |
BRD-K59369769-001-22-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.386975 | 4.693637 | 0.667255 | 0.691641 | 0.075853 | 0.104127 | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000911 |
BRD-K60866521-001-07-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.697982 | 0.200346 | -0.061353 | 0.862012 | 0.197878 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000911 |
BRD-K60997853-001-02-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | -0.037864 | 0.356799 | 0.59148 | 0.628943 | 0.589871 | 0.480734 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000911 |
BRD-K61192372-001-08-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.757103 | -0.711814 | 0.032568 | 0.886766 | 0.055046 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000911 |
BRD-K62008436-001-23-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.109019 | 3.137727 | 0.91055 | 0.466245 | 0.001866 | 0.002018 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000911 |
BRD-K62196610-001-01-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.273044 | 1.439573 | 0.716937 | 0.737622 | 0.302503 | 0.523621 | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000911 |
BRD-K62391742-001-09-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.834013 | -2.433509 | 0.20957 | 0.91322 | 0.097456 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000911 |
BRD-K62627508-001-01-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.053177 | -0.073582 | -0.094891 | 1 | 0.248378 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000911 |
BRD-K63504947-001-14-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.405135 | 1.234595 | 0.122631 | 1 | 0.02639 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000911 |
BRD-K63712959-001-01-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.98754 | 0.012534 | -0.061 | 0.993546 | 0.000248 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000911 |
BRD-K64052750-001-22-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.333309 | 2.642305 | 0.790274 | 0.630799 | 0.046344 | 0.070233 | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000911 |
BRD-K64881305-001-03-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.392327 | 2.464718 | 0.774441 | 0.64415 | 0.034034 | 0.063456 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000911 |
BRD-K66175015-001-12-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.245362 | 0.709554 | 0.642365 | 0.403248 | 0.003194 | 0.008268 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000911 |
BRD-K67844266-003-01-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.251033 | 2.734634 | 0.798715 | 0.647686 | 0.104092 | 0.134324 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000911 |
BRD-K69001009-001-02-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.136417 | 2.008318 | 0.466187 | 0.938445 | 5.77541 | 6.768299 | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000911 |
BRD-K69694239-001-02-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.19779 | 6.454392 | 0.790058 | 0.679806 | 0.207854 | 0.224717 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000911 |
BRD-K69776681-001-03-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.297679 | 3.717651 | 0.792958 | 0.610253 | 0.045825 | 0.058452 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000911 |
BRD-K70301465-001-05-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.077764 | 0.614715 | 0.703215 | 0.678241 | 0.406458 | 0.535108 | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000911 |
BRD-K70401845-001-15-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.408627 | 4.1996 | 0.642376 | 0.744133 | 0.150126 | 0.225021 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000911 |
BRD-K73838513-003-05-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.04204 | 2.516149 | 0.693287 | 0.914002 | 4.386155 | 4.541966 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000911 |
BRD-K74514084-003-09-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.853476 | 0.045523 | -0.016738 | 0.928451 | 0.219181 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000911 |
BRD-K75009076-001-02-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.001281 | 2.180897 | 0.41791 | 0.906745 | 4.326773 | 4.331864 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000911 |
BRD-K76210423-001-01-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.632075 | -0.090266 | -0.05737 | 0.764875 | 48.292527 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000911 |
BRD-K76239644-001-02-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.478482 | 1.378023 | 0.558177 | 0.664919 | 0.019473 | 0.190909 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000911 |
BRD-K76674262-001-03-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.156405 | 5.641731 | 0.693013 | 0.681342 | 0.255836 | 0.273426 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000911 |
BRD-K76908866-001-07-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.78036 | 6.798083 | 0.270948 | 0.887436 | 0.069185 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000911 |
BRD-K77625799-001-07-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.144302 | 0.289065 | -0.075832 | 0.661847 | 0.428553 | 1.391922 | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000911 |
BRD-K78431006-001-15-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.470702 | 0.346198 | 0.18195 | 0.755061 | 0.132391 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000911 |
BRD-K79254416-001-21-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.175808 | 0.335966 | 0.742696 | 0.589687 | 0.08058 | 0.29262 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000911 |
BRD-K81016934-001-02-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.692561 | 0.787996 | 0.152504 | 0.827166 | 0.041538 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000911 |
BRD-K81418486-001-44-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.226697 | 0.994649 | 0.552795 | 0.738823 | 0.391639 | 0.718825 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000911 |
BRD-K81473043-001-19-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.504734 | 3.692551 | 0.633575 | 0.879942 | 0.05945 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000911 |
BRD-K82135108-001-04-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.095326 | 0.874583 | 0.767363 | 0.300285 | 0.004596 | 0.005854 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000911 |
BRD-K82746043-001-19-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.123632 | 5.344614 | 0.776538 | 0.747554 | 0.610837 | 0.644171 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000911 |
BRD-K82818427-001-04-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.822351 | 0.321175 | 0.052059 | 0.916644 | 0.123527 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000911 |
BRD-K83029223-001-01-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.213443 | 1.364681 | 0.752216 | 0.634488 | 0.00688 | 0.010346 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000911 |
BRD-K83988098-001-02-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.38686 | 8.058823 | 0.678132 | 0.872307 | 0.020673 | 0.024859 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000911 |
BRD-K85402309-043-01-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.491461 | 0.201321 | 0.153081 | 0.768756 | 0.101385 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000911 |
BRD-K85606544-001-09-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.267775 | 0.985707 | 0.555113 | 0.645573 | 0.091425 | 0.199048 | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000911 |
BRD-K86118762-001-01-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.138141 | 2.137292 | 0.189172 | 1 | 0.07798 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000911 |
BRD-K86972824-001-01-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.187562 | -0.034606 | 0.005213 | 1 | 0.489788 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000911 |
BRD-K87737963-001-06-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | -0.746664 | 2.339772 | 0.529584 | 0.96046 | 11.851654 | 8.020444 | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000911 |
BRD-K87782578-001-01-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.201228 | 4.810813 | 0.743805 | 0.930536 | 4.315656 | 4.803146 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000911 |
BRD-K87909389-003-03-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.19842 | 4.680813 | 0.751115 | 0.663742 | 0.170596 | 0.190054 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000911 |
BRD-K88510285-001-17-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.23066 | 4.453685 | 0.71445 | 0.567275 | 0.01067 | 0.012259 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000911 |
BRD-K89014967-001-04-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.303011 | 0.838351 | 0.759523 | 0.581648 | 0.028428 | 0.086352 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000911 |
BRD-K92441787-001-04-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.075786 | -0.132387 | -0.096024 | 1 | 224.715764 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000911 |
BRD-K92723993-001-17-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.977904 | 0.093953 | 0.000216 | 0.984869 | 0.000018 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000911 |
BRD-K95142244-001-01-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.124461 | 1.801604 | 0.891261 | 0.618523 | 0.145798 | 0.170904 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000911 |
BRD-K96123349-236-02-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.712217 | 5.934439 | 0.294462 | 0.882701 | 0.191476 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000911 |
BRD-K98572433-001-02-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.211437 | 0.771651 | 0.878631 | 0.460209 | 0.011551 | 0.023551 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000911 |
BRD-K99113996-001-02-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.304923 | 0.959827 | 0.771008 | 0.560104 | 0.020837 | 0.055553 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000911 |
BRD-K99616396-001-05-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.812161 | 0.249219 | 0.008996 | 0.922378 | 0.376297 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000911 |
BRD-K99749624-001-07-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.723907 | -0.07062 | -0.045955 | 0.875741 | 0.004448 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000911 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.